Accumulating evidence suggests that angiotensin II type II (AT 2 ) receptor subtype negatively regulates cell proliferation in pathophysiological conditions associated with tissue remodeling. However, the mechanisms through which AT 2 receptor achieves this effect remain poorly understood. In this study, we demonstrate that expression of AT 2 receptor inhibits the proliferation of rat fibroblasts in a ligand-independent manner. The antiproliferative action of AT 2 is dependent on the density of surface receptors. We show that AT 2 receptor expression negatively regulates G1 phase progression in both cycling cells and G0-arrested cells stimulated to re-enter the cell cycle, but has no detectable effect on apoptosis. The delay in cell-cycle progression of AT 2 -expressing cells is associated with downregulation of cyclin E expression, decreased assembly of cyclin E-Cdk2 complexes, and the resulting attenuation of Cdk2 activation. The induction of Cdk4 expression and activity is also markedly attenuated, which likely contributes to the inhibition of cyclin E expression. Ectopic expression of Cdk4 alleviates the proliferation defect of AT 2 -expressing cells. These findings suggest that the growth-inhibitory effects of the AT 2 receptor are attributable in part to its spontaneous inhibitory action on the cell cycle machinery.
Introduction
The multifunctional peptide hormone angiotensin II (Ang II) binds to two distinct subtypes of receptors, designated as type I (AT 1 ) and type II (AT 2 ), which belong to the superfamily of seven transmembrane domain receptors (reviewed in de Gasparo et al., 2000; Kim and Iwao, 2000) . Most of the known hemodynamic and trophic actions of Ang II have been attributed to the AT 1 receptor subtype. Much less is known about the physiological roles of the AT 2 receptor. However, recent findings suggest that the AT 1 and AT 2 receptors may exert opposite effects on cell growth and blood pressure de Gasparo et al., 2000; Blume et al., 2001) .
The AT 2 receptor is widely and abundantly expressed in mesenchymal tissues of the developing embryo, but is found only at low levels in adult tissues (Grady et al., 1991; de Gasparo et al., 2000) . In the fetal aorta, the proliferative potential of vascular smooth muscle cells (VSMC) decreases at the latter stages of gestation when the density of AT 2 receptors increase; administration of an AT 2 antagonist in utero attenuates the developmentally regulated decrease in DNA synthesis (Nakajima et al., 1995; Hutchinson et al., 1999) . Expression of the AT 2 receptor is upregulated in pathophysiological conditions associated with tissue remodeling such as vascular injury, myocardial infarction, and wound healing (Viswanathan and Saavedra, 1992; Matsubara, 1998) . In vitro studies have shown that AT 2 receptor expression is low in exponentially growing cells and becomes high when cells reach confluence (Dudley and Summerfelt, 1993; Goto et al., 1997) . All these observations suggest that AT 2 receptors may regulate cell proliferation. In agreement with this idea, Stoll et al. (1995) first reported that AT 2 receptor activation inhibits the proliferation of endothelial cells. The antiproliferative action of the AT 2 receptor was also documented in VSMC (Nakajima et al., 1995) , PC12W pheochromocytoma cells (Meffert et al., 1996) , renomedullary cells (Maric et al., 1998) , and cardiac fibroblasts (Ohkubo et al., 1997) . Comparison of embryonic VSMC cultures from wild-type and AT 2 receptor null mice further indicated that AT À 2 cells display an exaggerated proliferative response to serum . The AT 2 receptor may also modulate cell number and contribute to tissue remodeling by inducing programmed cell death. Activation of endogenous or ectopically expressed AT 2 receptors has been associated with apoptotic changes in diverse cell types and tissues .
The molecular basis of the antiproliferative action of the AT 2 receptor subtype is unclear. In this study, we have stably expressed the AT 2 receptor in a rat fibroblast cell line to investigate its effect on cell proliferation. We demonstrate that the expression of the AT 2 receptor inhibits proliferation and cell cycle reentry of fibroblasts in a ligand-independent manner. The inhibition of cell proliferation is associated with a decreased expression of cyclin-dependent kinase 4 (Cdk4) and cyclin E, and the resulting attenuation of Cdk2 activation. Ectopic expression of AT 2 receptor has no detectable effect on apoptosis in these cells. We further show that the reduction of Cdk4 levels results from a decreased biosynthetic rate and increased protein turnover.
Results

Ectopic expression of AT 2 receptor is sufficient to inhibit proliferation of rat fibroblasts
We have stably expressed the AT 2 receptor in the immortalized rat fibroblast cell line Rat1, which is devoid of endogenous AT 2 receptors and do not show any functional response to Ang II. Rat1 cells infected with the AT 2 receptor gene (Rat1-AT 2 ) display a high increase in binding activity as compared to parental cells ( Figure 1a ). Computer analysis of 125 I-sarile binding data indicated that the AT 2 receptor binds the radioligand in a saturable manner with a binding capacity of 579 fmol/mg of protein (data not shown). The potency order of unlabeled ligands in competing for 125 I-sarile binding was CGP42112A ( (Figure 1b ), similar to that reported previously for the endogenous or cloned AT 2 receptor (Kambayashi et al., 1993; Mukoyama et al., 1993) . No significant binding of the AT 1 receptor antagonist losartan was observed even at micromolar concentrations. These results confirm that the stably expressed recombinant receptor exhibits the typical pharmacological properties of the AT 2 receptor. We first examined the impact of AT 2 receptor expression on the proliferation rate of Rat1 cells. As shown in Figure 1c , Rat1-AT 2 cells proliferated much slower than cells infected with empty virus (Rat1-V) in response to serum growth factors. In the exponential phase of proliferation, the doubling time of Rat1-AT 2 cells was about twofold longer than control cells (67 versus 29 h). No obvious morphological change typical of apoptosis or cell death was observed under these conditions. Moreover, trypan blue staining did not reveal any difference in cytotoxicity between the two cell lines (data not shown). Unexpectedly, the antiproliferative effect of the AT 2 receptor was completely independent of the presence of the agonist Ang II and was not blocked by the AT 2 -selective antagonist PD123319 (Figure 1c) . Flow cytometry analysis of subconfluent cells cultured in a serum-containing medium indicated that a higher percentage of Rat1-AT 2 cells are found in G1 (56 versus 47% for control cells), with a concomitant decrease in the proportion of cells in S and G2/M phases ( Figure 1d ).
We next analysed the effect of the AT 2 receptor on the kinetics of cell cycle re-entry of Rat1 fibroblasts. Control and Rat1-AT 2 cells were synchronized in G0 by contact inhibition and then replated at low density to allow synchronous re-entry into the cell cycle. The cells were collected at specific intervals and subjected to fluorescence-activated cell sorter (FACS) analysis. The progression of Rat1-AT 2 cells from G0 to S phase was severely delayed, with cells entering S phase at least 4 h later than their control counterpart (Figure 2a) . Again, expression of the AT 2 receptor was sufficient to inhibit cell-cycle progression. Treatment of Rat1-AT 2 cells with the agonist Ang II or the antagonist PD123319 did not modulate the antiproliferative action of the receptor (Figure 2b ). Together, these results indicate that AT 2 receptor expression negatively regulates G1 phase progression of both cycling cells and G0-arrested cells.
To further document the agonist-independent spontaneous activity of the AT 2 receptor, we analysed the proliferation of Rat1-AT 2 cell clones expressing increasing amounts of AT 2 receptor. According to the two-state receptor model, it is predicted that by increasing the receptor density, the absolute number of receptors in the active conformation will also increase and cause a detectable response (Bond and Bouvier, 1998) . Consistent with this model, the proliferation rate of Rat1-AT 2 clones inversely correlated with the level of AT 2 receptors present at the cell surface (Figure 3 ).
Expression of AT 2 receptor does not induce apoptosis in rat fibroblasts
It has been reported that overexpression of AT 2 receptor promotes apoptosis in different cellular models , suggesting that apoptotic changes may contribute to the overall inhibitory effect of the AT 2 receptor on cell-doubling time. However, no significant numbers of sub-G1 cells were detected by FACS analysis either in exponentially proliferating Rat1-AT 2 cells (Figure 1d ) or in cells deprived of serum for 24 h (Figure 2a ). TUNEL analysis indicated that the percentage of cells undergoing apoptosis was comparable between the two populations of cells after serum Figure 4 ). Also, no difference was observed between Rat1-V and Rat1-AT 2 cells after treatment with the topoisomerase I inhibitor camptothecin, which is a strong apoptotic inducer. Thus, we conclude that the AT 2 receptor inhibits proliferation of rat fibroblasts by altering cell-cycle kinetics and not by increasing cell death due to apoptosis.
AT 2 receptor downregulates Cdk4 and cyclin E expression
To define the molecular basis of this inhibitory action of AT 2 receptor on cell-cycle progression, we examined the consequences of AT 2 expression on key regulators of the G1 phase (Sherr, 1996; Reed, 1997) . For these experiments, control and Rat1-AT 2 cells were arrested in G0 by contact inhibition, and then allowed to re-enter synchronously the cell cycle by reseeding at low density. The expression of cell-cycle regulators was monitored at different intervals by immunoblot analysis (Figure 5a ). The expression of cyclin D1 slightly increased during cell-cycle re-entry and was comparable in both cell lines. In contrast, the induction of cyclin E protein was significantly downregulated in AT 2 -expressing Rat1 cells. No change in the expression level of Cdk2 catalytic subunit was observed, but the induction of Cdk4 was significantly attenuated in Rat1-AT 2 cells. We then asked whether the reduction in the levels of cyclin E observed in Rat1-AT 2 cells was associated with a corresponding decrease in the enzymatic activity of Cdk2, its catalytic partner. Cdk2 complexes were immunoprecipitated from cell lysates and the phosphotransferase activity of Cdk2 was measured by immune complex kinase assay using histone H1 as substrate. As shown in Figure 5b , the activation of Cdk2 by serum was markedly attenuated in Rat1-AT 2 cells. In addition, the onset of Cdk2 activation was delayed by B4 h in these cells, in good correlation with the lengthening of G1 phase. Immunoblot analysis of cyclin E immunoprecipitates confirmed that Rat1-AT 2 cells contain lessassembled cyclin E-Cdk2 complexes ( Figure 5c ).
The retinoblastoma protein (Rb) is an important regulator of G1-S phase transition and a target of G1 Cdks (Weinberg, 1995) . The generally accepted view is that cyclin D-Cdk4/6 initiates Rb phosphorylation in mid-G1 phase, after which cyclin E-Cdk2 becomes active and completes this process by phosphorylating Rb on additional sites (Harbour and Dean, 2000) . Rb phosphorylation disrupts its association with bound E2F family members, allowing the coordinated transcription of genes required for DNA replication. We therefore examined the phosphorylation profile of Rb during cell-cycle progression of control and Rat1-AT 2 (Figure 5d ). However, the phosphorylation of Rb was markedly decreased in cells expressing the AT 2 receptor. We further examined the phosphorylation of Rb at specific regulatory sites using phospho-specific antibodies. A marked decrease in the phosphorylation of Rb on serine residues 807, 811, and 780, three sites specifically recognized by Cdk4 (Kitagawa et al., 1996; Zarkowska and Mittnacht, 1997) , was observed in Rat1-AT 2 cells (Figure 5e ). This observation confirms that the decrease in Cdk4 protein levels observed in AT 2 -expressing Rat1 cells is accompanied by a decrease in Cdk4 enzymatic activity. The activity of Cdk2 is also negatively regulated by its interaction with the Cip/Kip family of Cdk inhibitors (Sherr and Roberts, 1995) . To determine whether changes in the levels of Cdk inhibitors could be responsible in part for the differences observed in Cdk2 activity, we measured the levels of p27
Kip1 and p57
Kip2 proteins in control and Rat1-AT 2 cells. Figure 5f shows that the abundance of p27
Kip2
inhibitors is comparable throughout G1 in the two cell populations. The other member of the family, p21
Cip1
, is not expressed in Rat1 fibroblasts (Allan et al., 2000) . We conclude from these results that the lower Cdk2 activity observed in Rat1-AT 2 cells is likely attributable to a decrease in cyclin E expression.
If downregulation of Cdk4 expression is responsible for the observed defect of G1 progression in Rat1-AT 2 cells, then ectopic expression of Cdk4 should rescue, at least in part, the proliferation defect. To test this hypothesis, Rat1-V and Rat1-AT 2 cells were 
AT 2 receptor represses Cdk4 biosynthesis and increases its degradation rate
We next addressed the question of how Cdk4 levels are regulated by the AT 2 receptor. Three mechanisms have been reported to control Cdk4 expression. First, the Cdk4 gene was identified as a target of c-Myc by serial analysis of gene expression (SAGE) analysis (Hermeking et al., 2000) . However, we found that expression of c-Myc was equivalent in the two cell lines (data not shown) and Northern blot analysis did not reveal any difference in Cdk4 mRNA levels (Figure 7a) . Second, treatment with the antimitogenic cytokine TGF-b was shown to inhibit Cdk4 expression by reducing its rate of synthesis (Ewen et al., 1993 (Ewen et al., , 1995 Geng and Weinberg, 1993) . We therefore assessed the rate of Cdk4 biosynthesis in control and Rat1-AT 2 cells by pulse-labeling analysis. These experiments revealed that the rate of Cdk4 synthesis was approximately twofold lower in AT 2 -expressing cells (Figure 7b ). Interestingly, it was previously shown that inhibition of Cdk4 synthesis by TGF-b is dependent on p53, which binds directly to the 5 0 UTR of Cdk4 mRNA and represses translation (Ewen et al., 1995; Miller et al., 2000) . To determine whether the AT 2 receptor employs a similar mechanism, we monitored the expression and activity of p53. No significant difference in the expression level of p53 was observed between control and Rat1-AT 2 cells (Figure 7c , upper panel). The transcriptional activity of p53 was measured using a p21 promoter construct that contains p53 binding sites (el-Deiry et al., 1993) . Similarly, no difference in the activity of the p21 promoter could be observed between the two cell lines. These results suggest that the AT 2 receptor inhibits Cdk4 synthesis by a novel p53-independent mechanism.
The abundance of Cdk4, like that of many other cellcycle regulators, is also regulated at the level of protein turnover through the ubiquitin-proteasome degradation pathway (Wang et al., 2002) . We thus evaluated the effect of AT 2 receptor expression on the turnover of Cdk4 by cycloheximide-chase experiments (Figure 7d ). G0-arrested cells were stimulated to re-enter the cell cycle with serum and cycloheximide (CHX) was added at different times after stimulation. The turnover of Cdk4 was monitored by immunoblot analysis. The halflife of Cdk4 in quiescent Rat1 cells was estimated to be 4.1 h, a value comparable to what has been reported in primary hepatocytes (Wang et al., 2002) . Notably, the stability of Cdk4 decreases as cells progress into the cell cycle, possibly explaining the transient reduction in Cdk4 steady-state protein levels observed during G1 progression (see Figure 5a) . The half-life of Cdk4 was clearly shorter in Rat1-AT 2 cells, whether CHX was added to G0-synchronized cells, or after 6 or 18 h of release from growth arrest. We conclude from these results that AT 2 receptor downregulates Cdk4 expression by affecting both the synthesis and degradation of the protein.
Discussion
In the classical view of drug-receptor interactions, the receptor is thought to exist in an inactive conformation (R), which requires an agonist-induced conformational change for coupling to the G protein. However, this concept has recently been challenged following the observation that many G protein-coupled receptors exhibit spontaneous activity in the absence of agonist stimulation and that mutations in different domains of the receptor can unveil this ligand-independent activity (reviewed in Bond and Bouvier, 1998; Leurs et al., 1998) . The simplest model proposes that the receptor exists in an equilibrium between two distinct conformational states, an inactive R and an active R * state. In the absence of ligand, the level of basal receptor activity is determined by the spontaneous isomerization to the active R * conformation. This model also predicts that the absolute number of active receptors (R * ) will increase as a function of receptor density. In a recent study, Akishita et al. (1999) observed that the growth difference between VSMC isolated from wild-type and AT 2 À mice was maintained even in the absence of Ang II and was not affected by the AT 2 antagonist PD123319. Consistent with this observation, we demonstrate here that the AT 2 receptor inhibits proliferation of rat and Karnik, 2000) reported that overexpression of AT 2 receptor induces ligand-independent apoptosis in Chinese hamster ovary (CHO) cells and in the A7r5 smooth muscle cell line. In contrast to these findings, we did not observe any significant proapoptotic effect of the AT 2 receptor in exponentially proliferating or serum-starved Rat1 fibroblasts. Similarly, no apoptotic changes were observed in cardiac myocytes from transgenic mice overexpressing the AT 2 receptor in the heart (Masaki et al., 1998) . These observations suggest that the proapoptotic effect of the AT 2 receptor may be celltype specific. However, it should be noted that the induction of apoptosis associated with AT 2 receptor expression can only be revealed under extreme experimental conditions, such as serum deprivation for several days. This raises questions about the importance of this pathway in the in vivo physiological context and suggests that the main action of AT 2 receptor during embryonic development or tissue remodeling may be inhibition of cell proliferation.
The signaling mechanisms of the AT 2 receptor and the molecular basis of its antiproliferative action are still poorly understood (de Gasparo et al., 2000; Nouet and Nahmias, 2000) . Stimulation of the AT 2 receptor by Ang II has been shown to attenuate serum and AT 1 receptor-mediated activation of the mitogen-activated protein kinases ERK1/2 in cultured vascular smooth muscle cells and neuronal cells (Nakajima et al., 1995; arrest for the times indicated were treated with CHX and the expression of Cdk4 was analysed by immunoblotting. Different exposure times are shown in order to detect Cdk4 in all the conditions tested. Immunoblots were quantified by densitometric analysis and the mean half-lives were calculated from three different experiments Huang et al., 1996; Yamada et al., 1996; Bedecs et al., 1997) , and in the heart of transgenic mice overexpressing the AT 2 receptor (Masaki et al., 1998) . However, it is unlikely that inhibition of the ERK mitogen-activated protein kinase pathway is responsible for the antiproliferative action of the AT 2 receptor, at least in rat fibroblasts. First, we did not observe any significant effect of AT 2 overexpression on the amplitude or duration of ERK1 activation by serum growth factors in Rat1 cells (data not shown). Second, the expression of cyclin D1, which is the major target of the ERK1/2 pathway during cell-cycle re-entry (Lavoie et al., 1996) , was similar in control and Rat1-AT 2 cells.
Cyclin E-dependent Cdk2 activity is essential and rate limiting for G1-S phase transition in mammalian cells (see Reed (1997) ; Sherr (1996) ; Sherr and Roberts (1999) for a review). Inactivation of cyclin E, or inhibition of Cdk2 activity by expression of CDK inhibitors or dominant-negative Cdk2 arrests cells in G1. Conversely, overexpression of cyclin E leads to premature S phase entry. Cdk2 participates in a number of key cellular processes that are required for G1/S transition to take place in a coordinated fashion. These include the full inactivation of pRb, which influences the transcriptional activity of E2F, histone biosynthesis, pre-mRNA splicing, and the initiation of DNA replication (Ewen, 2000) . Here, we show that AT 2 receptor expression markedly inhibits serum-dependent activation of Cdk2, providing a molecular basis for the antiproliferative action of this receptor. The inhibition of Cdk2 is associated with a concomitant decrease in Cdk4 activity and cyclin E expression, with no change in the levels of CDK inhibitors. The expression of cyclin E is dependent on the prior assembly and activation of Cdk4/6-cyclin D complexes, which initiate the phosphorylation of Rb and relieve its repression on the Cyclin E gene (Harbour and Dean, 2000) . The induction of cyclin E, which in turn associates with Cdk2 to enforce Rb phosphorylation, creates a positive feedback loop that helps contribute to the irreversibility of S phase entry. Consistent with the decrease in Cdk4 activity and cyclin E expression, we indeed observed a marked inhibition of Rb phosphorylation in Rat1-AT 2 cells. These observations suggest that Cdk4 is the primary target of AT 2 action on the cell cycle, and that inhibition of Cdk4 activity is responsible in part for the subsequent downregulation of cyclin E expression and cyclin ECdk2 activation. The decrease in Cdk4 abundance observed in AT 2 -expressing cells may also contribute to the inhibition of Cdk2 activity by favoring the redistribution of p27
Kip1 from cyclin D-Cdk4 to cyclin E-Cdk2 complexes.
It is interesting to note that few antiproliferative agents or receptors have been shown to directly inhibit Cdk4 expression. The best-described example is TGFb, which downregulates Cdk4 expression by repressing translation of Cdk4 mRNA in a p53-dependent manner (Ewen et al., 1993 (Ewen et al., , 1995 Geng and Weinberg, 1993 ). Here we show that AT 2 receptor expression inhibits Cdk4 biosynthesis without affecting the levels of Cdk4 mRNA. Contrary to TGFb, the repression of Cdk4 synthesis appears to be independent of p53. Additional work will be required to identify putative trans-acting factors that mediate the inhibitory effect of AT 2 receptor on Cdk4 translation.
Materials and methods
Cell culture, reagents, and antibodies Rat1 cells were cultured as described previously (Meloche, 1995) . The cells were synchronized in G0 by incubation for 24 h in serum-free DMEM/F12 (1 : 1) supplemented with 15 mm HEPES (pH 7.4) and 0.1% bovine serum albumin. For certain experiments, the cells were arrested by contact inhibition and replated at low confluence to allow cell-cycle reentry.
Ang ]Ang II (sarile) were purchased from Hukabel Scientific. The source of Ang II receptor antagonists has been described previously (Lambert et al., 1995) .
125
I-sarile was prepared by radioiodination of sarile using a solid-phase method (Lambert et al., 1995) . Commercial antibodies were from the following suppliers: anti-cyclin D1 (DCS-6), antiCdk4 (DCS-35), anti-Rb (Ab-6), and anti-p53 (clone PAb 240) from NeoMarkers; anti-phospho-Rb from Cell Signaling; anticyclin E (sc-481), anti-Cdk2 (sc-163), anti-p27
Kip1 (sc-528), anti-p57
Kip2 (sc-8298), anti-HA (Y-11), and anti-c-Myc (N-262) from Santa Cruz Biotechnology.
Generation of Rat1-AT 2 cell lines A 1.3 kb. genomic fragment containing the entire coding sequence of the human AT 2 receptor gene (Chassagne et al., 1995) was subcloned into the retroviral expression vector pLNCX (Miller and Rosman, 1989) to generate pLNCX-AT 2 . Empty pLNCX vector and pLNCX-AT 2 were transfected with Lipofectamine (Life Technologies) into the amphotropic retrovirus packaging cell line fCRIP (Danos and Mulligan, 1988) and stably transfected cells were selected in a complete medium containing 0.4 mg/ml of G418 (Life Technologies). For infection of Rat1 cells, viral supernatants were harvested from helper-free retroviral producer cell lines and applied to subconfluent cultures of Rat1 cells in the presence of 8 mg/ml polybrene for 24 h. The infected Rat1 cells were then selected, expanded into cell lines, and screened by whole-cell radioligand binding assay. The results presented are representative of two independent Rat1-AT 2 cell lines. A population of cells infected with empty retrovirus and referred to as Rat1-V was used as control.
Receptor binding assays
Membranes from Rat1-V and Rat1-AT 2 cells were prepared as previously described (Meloche et al., 1986) . Competition binding studies were carried out by incubating Rat1 cell membranes for 1 h at 251C with B0.2 nm 125 I-sarile and varying concentrations of the indicated competing ligands in 0.25 ml of binding buffer (50 mm Tris-HCl (pH 7.4), 150 mm NaCl, 0.1 mm EDTA, 1 mm MgCl 2 , and 0.1% heat-inactivated bovine serum albumin). Bound 125 I-sarile was separated from free ligand by rapid filtration on GF/B filters, and the filters were counted for radioactivity (Lambert et al., 1995) . Averages of duplicate determinations of bound 125 I-sarile were used for data analysis. Binding data were analysed by nonlinear leastsquares curve fitting using the SCAFIT computer program (De Le´an et al., 1982) . Equilibrium binding constants are reported as dissociation constant (K d ), and receptor concentration is expressed as fmol/mg of protein.
Proliferation assays, cell cycle analysis, and apoptosis
Cell proliferation was measured using the colorimetric MTT assay (Denizot and Lang, 1986) . Cells were plated in quadruplicate in flat-bottomed 96-well plates and treated as indicated. At specific time points, the medium was removed and 50 ml of DMEM containing 1 mg/ml MTT was added to each well. After incubation for 3 h at 371C, the wells were decanted and the formazan product was solubilized in 100 ml of 2% glycine-NaOH (pH 11) in DMSO. The absorbance of the dye was measured at 550 nm.
For cell-cycle analysis, exponentially proliferating or G0-synchronized cells allowed to reenter the cell cycle were trypsinized, fixed in cold 70% ethanol, and kept at -201C until FACS analysis. The cells were then washed with PBS, and incubated on ice for 30 min in PI buffer (0.1 sodium citrate, 50 mg/ml propidium iodide, 0.2 mg/ml RNAse). Fluorescence was recorded on a Coulter epics XL flow cytometer and the cell cycle profiles were determined using the Multicycle AV software.
For analysis of BrdU incorporation, cells plated on glass coverslips were transfected using FuGENE 6 reagent (Roche Molecular Biochemicals) with HA-GFP (Coulombe P and Meloche S, unpublished) or Cdk4-HA expression constructs. After serum deprivation, the cells were stimulated for 20 h with 10% serum, and BrdU (10 mm) was added during the last 8 h of treatment. The cells were fixed with 3.7% paraformaldehyde/ PBS for 20 min at 371C. After quenching in 0.1 m glycine for 5 min, the cells were permeabilized by incubation in 0.1% Triton X-100 for 5 min at room temperature. The transfected proteins were detected by staining with anti-HA as primary antibody and FITC-conjugated anti-rabbit IgG as secondary reagent. Then, DNA was denatured with HCl 2 n for 10 min at room temperature. Staining for BrdU incorporation was performed by incubating cells for 1 h at 371C with anti-BrdU antibody, followed by incubation with rhodamine-conjugated anti-mouse IgG as secondary reagent. DAPI staining was performed to visualize the nuclei. Cell samples were analysed by fluorescence microscopy (Leica DM RB). The results are expressed as the percentage of transfected cells showing nuclear labeling for BrdU.
Apoptotic cell death was evaluated by TUNEL assay. Briefly, cells were plated on glass coverslips and serum-starved for 24 h, prior to stimulation with 10% serum. The cells were fixed with 4% paraformaldehyde for 1 h at room temperature and permeabilized (0.1% Triton X-100, 0.1% sodium citrate) for 2 min on ice. TUNEL analysis was performed using the Cell Death Detection Kit (Roche Diagnostics) according to the manufacturer's instructions. The percentage of apoptotic cells was evaluated by fluorescence microscopy.
Immunoblot analysis and Cdk2 assays
Immunoblot analysis of cell-cycle regulators was performed as described previously (Servant et al., 2000) . For the analysis of cyclin E-Cdk2 complex formation, total lysate proteins (300 mg) were incubated for 4 h at 41C with anti-cyclin E antibody preadsorbed to protein A-Sepharose beads. The immunoprecipitated proteins were resolved by SDS-gel electrophoresis and analysed by immunobloting with antiCdk2 antibody.
The phosphotransferase activity of Cdk2 was measured by immune complex kinase assay using histone H1 as substrate as described previously (Meloche, 1995) .
Northern blot analysis
Isolation of total RNA and Northern blot analysis was carried out as described previously (Servant et al., 2000) using a DNA probe specific for the 3 0 UTR of rat Cdk4.
Biosynthetic labeling and cycloheximide-chase experiments
For labeling newly synthesized Cdk4 proteins, cells were stimulated for the indicated times, rinsed with methionine-and cysteine-free medium, and then incubated with 250 mCi/ml of [ 35 S]methionine and [ 35 S]cysteine. Labeling was allowed to proceed for the last 30 min. Cell lysis and immunoprecipitation of Cdk4 were conducted as described (Servant et al., 2000) . The labeled Cdk4 protein was detected by fluorography and quantified using a PhosphorImager apparatus.
For cycloheximide-chase experiments, the cells were arrested in G0 by contact inhibition and allowed to re-enter the cell cycle as described above. At different stages of the cell cycle, CHX (100 mg/ml) was added for the times indicated. The expression of Cdk4 was monitored by immunoblot analysis.
Reporter gene assays
Cells in 24-well plates were transiently transfected with the p21 promoter luciferase reporter (el-Deiry et al., 1993) and pcDNA3.1-His/LacZ (ratio 3 : 1) using the FuGENE 6 reagent. The total DNA amount was kept at 1.2 mg total. After 24 h, the cells were serum-starved and stimulated for the times indicated. The cells were washed with ice-cold PBS and lysed in 150 ml of lysis buffer (50 mm Tris-HCl, pH 7.8, 1 mm dithiothreitol, 1% Triton X-100). The activity of luciferase was measured on a model 1250 luminometer and normalized to b-galactosidase activity using a spectrophotometric assay.
